Skip to main content
Caplight Logo









Bioheng Therapeutics

Bioheng Therapeutics

Private
NanjingHealthcare & Life Scienceshttps://www.imvivabio.com/

Last Round

Series B

Mar 24, 2021

Total Funding Raised

$97.97M

Company Overview

Bioheng Therapeutics is a biopharmaceutical company that develops allogeneic, off-the-shelf universal CAR-T cell therapies for the treatment of cancer and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

allogeneic CAR-Toff-the-shelf cell therapyCAR-T therapyimmune evasioncell engineeringhematological malignanciesautoimmune diseaseready-to-use therapybiotechnologyclinical-stage biotechT-cell therapynext-gen CAR-Tcell therapy manufacturingGMP manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bioheng Therapeutics Comparables

Compare Bioheng Therapeutics with similar companies based on industry and business-model similarity.

Bioheng Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Allotera Therapeutics
89%
AvenCell
82%
Century Therapeutics
78%

Bioheng Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 24, 2021
Series AFeb 14, 2019
AngelApr 1, 2018

Key People

Founding team and executive leadership

Lu Han

Co-founder CEO

Founding Team

Jenny Ni

Chief Technology Officer

Executive Team

Bioheng Therapeutics Investors

Notable investors and investment history

Bioheng Therapeutics investors
InvestorRounds
Lanchi VenturesSeries B
Hillhouse InvestmentSeries B
Lanchi VenturesSeries B
GL VenturesSeries B
Octagon Capital AdvisorsSeries B
BlueRun VenturesSeries B
Octagon CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 16, 2025

    Presented latest clinical data for CAR-T product CTD402 at an event.

Bioheng Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Bioheng Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Bioheng Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNanjing
Employee Range27
Year Founded2017
Last FundingMar 24, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?